Skip to main content
OpenTrials
Completed

NCT Number: NCT05133999

Iron and Retinopathy of Prematurity (ROP)

The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

Preterm infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birth weight will be included. Iron parameters in plasma will be measured during the first month of life. Retinopathy of prematurity (ROP) will be screened as currently recommended. The relationship between plasma iron parameters and ROP development and/or severity will be established.

Completed

Looking for future studies?

Notify Me

Key information

Age range

24 week–31 week

Sex eligibility

All sexes

Study type

Observational

Primary location

Ophtalmology department _ Necker Enfants Malades Hospital, Paris, France

Loading trial locations.

About this study

The incidence of ROP, the main cause of vision impairment in children, is increasing parallel to the recent changes in practices targeting higher oxygen saturation in preterm babies in many countries following the publication of five trials that showed higher rates of death with lower oxygen saturations. The main risk factor for ROP development is oxygen excess. Oxygen contributes to the formation of reactive oxygen species and to lipid peroxidation which leads to vasoconstriction, vascular cytotoxicity, and arrest of vascular development causing ischemia of retinal neurons, thereby promoting the development of ROP.

90% of extremely low birth weight infants need red blood cell transfusions (RBCT) due to their immature erythropoiesis, frequent blood sampling and small circulating blood volume. RBCT are a major source of iron overload and ferritin plasma levels may remain elevated for several weeks after transfusions. It has been shown that blood transfusion is a risk factor of ROP in preterm infants. However, whether this relationship is mediated by an increased iron load remains controversial.

Only two studies, conducted before the 2000s, identified plasma iron overload as a risk factor for ROP. These studies with a limited number of patients, showed contradictory results, failing to draw a conclusion.

Excess iron worsens oxidative stress. Iron catalyzes the Fenton reaction which leads to the formation of reactive oxygen species. In addition a transferrin deficiency (the main iron chelator) has been suggested in premature infants. The oxidative stress observed in ROP could therefore be the consequence not only of oxygen therapy but also of iron overload.

The main objective of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.

The secondary aims/objectives are :

  • Determine whether low transferrin level in plasma is an independent risk factor for ROP development and severity.
  • Determine whether iron parameters imbalance in plasma are a risk factor for other comorbidities in Preterm infants i.e.:
  • 1) sepsis
  • 2) severe bronchopulmonary dysplasia
  • 3) necrotizing enterocolitis (stage 2 or 3)
  • 4) cystic periventricular leukomalacia
  • 5) grade III or IV intraventricular haemorrhage

Study duration will be 29 months, with an inclusion period of 24 months and a last visit for ROP evaluation at 45 week's post-menstrual age (PMA).

A total of 175 patients should be included: 35 with ROP and 140 without ROP.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All infants born at <31 week's post-menstrual age (PMA) or ≤1250g of birthweight
  • Admitted at two neonatology departments (level III) from birth
  • With non-opposition consent of two parents

Exclusion criteria

  • Congenital malformation
  • Life-threatening condition (not expected to survive more than a few days)
  • Absence of health care protection.

Treatment and study plan

Plasma determination of iron, transferrin and ferritin

Biological

Iron, transferrin and ferritin levels in plasma

Fundus Examination by wide field digital imaging camera (PanocamTM camera)

Other

ROP screening using wide field digital retinal imaging according to current recommendations.

Primary outcomes

  1. ROP screening

    Time frame: From 31 to 45 weeks' post menstrual age (PMA) [= (term + 4 weeks of life)].

    Presence of ROP development (any stage / any zone in at least one eye) during follow-up.

  2. Levels of transferrin saturation in plasma at 1 week of life

    Time frame: at 1 week of life

    Blood dosage

Secondary outcomes

  1. Levels of iron

    Time frame: at birth, 2, 3, and 4 weeks of life

    Blood dosage, in µmol/l

  2. Levels of transferrin

    Time frame: at birth, 2, 3, and 4 weeks of life

    Blood dosage, in g/l

  3. Levels of ferritin

    Time frame: at birth, 2, 3, and 4 weeks of life

    Blood dosage, in µg/l

  4. ROP's highest stage

    Time frame: during follow-up about 5 months, up to 45 weeks' PMA

    according to International Classification of Retinopathy of Prematury (ICROP3 classification)

  5. Need of treatment for ROP

    Time frame: during follow-up about 5 months, up to 45 weeks' PMA

    Laser, anti-VEGF injections, surgery

  6. Number of each intervention

    Time frame: during follow-up about 5 months, up to 45 weeks' PMA

    Number of each intervention if a treatment was needed

  7. Death or presence of severe co-morbidities in preterm infant

    Time frame: At 36 weeks' PMA

    death or presence of monitoring :

    • severe bronchopulmonary dysplasia or 2) necrotizing enterocolitis (stage 2 or 3), or 3) cavitary periventricular leucomalacia or 4) intraventricular haemorrhage (grade III or IV).

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Fondation Université de Paris
  • Fondation VISIO
  • URC-CIC Paris Descartes Necker Cochin

Registry information

Official study title

Iron, Transferrin and Retinopathy of Prematurity (ROP): Towards New Pathophysiological Mechanisms.

Acronym: Fer-ROP

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Nov 24, 2021
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.